Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data

被引：12
作者：
Ruggiero, Angelo [1 ]
Megna, Matteo [1 ]
Fabbrocini, Gabriella [1 ]
Ocampo-Garza, Sonia Sofia [1 ,2 ]
机构：
[1] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Via Pansini 5, I-80131 Naples, Italy
[2] Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose Eleuterio Gonzalez, Dermatol Dept, Monterrey, NL, Mexico
来源：
IMMUNOLOGIC RESEARCH | 2023年 / 71卷 / 03期
关键词：
Psoriasis; Treatments; Anti-IL23; Guselkumab; Tildrakizumab; Risankizumab; MONOCLONAL-ANTIBODY; PLAQUE PSORIASIS; VOYAGE; GUSELKUMAB; SAFETY; ADALIMUMAB; EFFICACY; MODERATE; TILDRAKIZUMAB; RISANKIZUMAB;
D O I：
10.1007/s12026-022-09356-y
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Nowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: clinical trials (CTs) and real-world experiences data (RWE). Notably, the two sources differ from one another, but together, they complement information and current knowledge on both efficacy and safety of biological therapy. We carry out a review on CTs and RWE reports on the latest group of biological approved for moderate-to-severe psoriasis: anti-IL23 (guselkumab, risankizumab, and tildrakizumab).
引用
收藏
页码：328 / 355
页数：28
相关论文
共 101 条
[1]   Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? [J].
Amin, Mina ;
No, Daniel J. ;
Egeberg, Alexander ;
Wu, Jashin J. .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (01) :1-13
[2]   Cutaneous involvement during COVID-19 pandemic: an emerging sign of infection [J].
Annunziata, M. C. ;
Patri, A. ;
Ruggiero, A. ;
Di Guida, A. ;
Menicanti, C. ;
Greco, V. ;
Fabbrocini, G. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (11) :E680-E682
[3]  
[Anonymous], About us
[4]  
Bartos Gregory, 2018, Dermatol Online J, V24
[5]   Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study [J].
Benhadou, F. ;
Ghislain, P. D. ;
Guiot, F. ;
Willaert, F. ;
Del Marmol, V. ;
Lambert, J. ;
Soenen, R. ;
Fierens, H. ;
de la Brassinne, M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (12) :E837-E839
[6]   Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease [J].
Berman, Hannah S. ;
Villa, Natalie M. ;
Shi, Vivian Y. ;
Hsiao, Jennifer L. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (02) :261-263
[7]  
Blauvelt A, 2020, BRIT J DERMATOL, V182, P1348, DOI [10.1111/bjd.19072, 10.1111/bjd.18851]
[8]   Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial [J].
Blauvelt, Andrew ;
Leonardi, Craig L. ;
Gooderham, Melinda ;
Papp, Kim A. ;
Philipp, Sandra ;
Wu, Jashin J. ;
Igarashi, Atsuyuki ;
Flack, Mary ;
Geng, Ziqian ;
Wu, Tianshuang ;
Camez, Anne ;
Williams, David ;
Langley, Richard G. .
JAMA DERMATOLOGY, 2020, 156 (06) :649-658
[9]   Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial [J].
Blauvelt, Andrew ;
Papp, Kim A. ;
Griffiths, Christopher E. M. ;
Randazzo, Bruce ;
Wasfi, Yasmine ;
Shen, Yaung-Kaung ;
Li, Shu ;
Kimball, Alexa B. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) :405-417
[10]   Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience [J].
Bonifati, Claudio ;
Morrone, Aldo ;
Cristaudo, Antonio ;
Graceffa, Dario .
DERMATOLOGIC THERAPY, 2021, 34 (01)
12345678910